Beliz Akçakoca
Research Subjects
Beliz Akçakoca has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Arzu Yilmaztepe Oral
BURSA ULUDAĞ ÜNİVERSİTESİ, TIP FAKÜLTESİ
1 shared publication - Ayşe Armağan Aydoğan
Intensive Care Unit, Inonu University Turgut Ozal Medical Center, Malatya, Türkiye
1 shared publication - Göksel Aydoğan
Bursa Uludağ Üniversitesi Tıp Fakültesi, Acil Tıp Anabilim Dalı, Bursa, Türkiye
1 shared publication - Vahide Aslıhan Durak
Bursa Uludağ Üniversitesi Tıp Fakültesi, Acil Tıp Anabilim Dalı, Bursa, Türkiye
1 shared publication - Yasemin Dinç
Department of Neurology, Uludag University Faculty Of Medicine, Bursa, Turkiye
1 shared publication
Latest Publications
- 30 September 2025
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 16 (3) , 600-609
The relationship between serum ischemia-modified albumin levels and prognosis in acute ischemic stroke
Aim: This study aimed to investigate the association between serum ischemia-modified albumin (IMA) levels, stroke severity, and functional outcomes in adult patients diagnosed with acute ischemic stroke (AIS) in the emergency department. Material and Methods: In this prospective observational study, 40 AIS patients and 20 age- and sex-matched healthy controls were enrolled. Serum IMA levels were measured at admission using a commercial ELISA kit. Stroke severity was assessed with the National Institutes of Health Stroke Scale (NIHSS), and functional outcomes at 3 months were determined using the modified Rankin Scale (mRS), with scores ≥2 defined as poor functional outcome (PFO). Results: Median IMA levels were significantly higher in AIS patients than controls. Elevated IMA was independently associated with AIS (adjusted OR: 1.18, 95% CI: 1.03–1.35, p = 0.015), severe stroke (adjusted OR: 1.38, 95% CI: 1.06–1.83, p = 0.018), and PFO at 3 months (adjusted OR: 1.16, 95% CI: 1.04–1.30, p = 0.008). ROC analysis identified IMA cutoffs of >58 ng/mL for AIS (AUC: 0.859), >76.7 ng/mL for severe stroke (AUC: 0.890), and >65.4 ng/mL for PFO (AUC: 0.854). Conclusion: Serum IMA levels are elevated in AIS and correlate with both initial stroke severity and short-term functional outcomes. IMA may serve as a rapid, cost-effective biomarker for early risk stratification in AIS.
- 30 September 2025
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 16 (3) , 600-609
The relationship between serum ischemia-modified albumin levels and prognosis in acute ischemic stroke
Aim: This study aimed to investigate the association between serum ischemia-modified albumin (IMA) levels, stroke severity, and functional outcomes in adult patients diagnosed with acute ischemic stroke (AIS) in the emergency department. Material and Methods: In this prospective observational study, 40 AIS patients and 20 age- and sex-matched healthy controls were enrolled. Serum IMA levels were measured at admission using a commercial ELISA kit. Stroke severity was assessed with the National Institutes of Health Stroke Scale (NIHSS), and functional outcomes at 3 months were determined using the modified Rankin Scale (mRS), with scores ≥2 defined as poor functional outcome (PFO). Results: Median IMA levels were significantly higher in AIS patients than controls. Elevated IMA was independently associated with AIS (adjusted OR: 1.18, 95% CI: 1.03–1.35, p = 0.015), severe stroke (adjusted OR: 1.38, 95% CI: 1.06–1.83, p = 0.018), and PFO at 3 months (adjusted OR: 1.16, 95% CI: 1.04–1.30, p = 0.008). ROC analysis identified IMA cutoffs of >58 ng/mL for AIS (AUC: 0.859), >76.7 ng/mL for severe stroke (AUC: 0.890), and >65.4 ng/mL for PFO (AUC: 0.854). Conclusion: Serum IMA levels are elevated in AIS and correlate with both initial stroke severity and short-term functional outcomes. IMA may serve as a rapid, cost-effective biomarker for early risk stratification in AIS.